Promising results with Almirall's once daily long acting beta agonist (LABA) expected to lead to a development and commercialization partnership in 2009

· The pharmaceutical company Almirall successfully completed a phase II study demonstrating superior bronchodilation to twice daily salmeterol and 24-hour efficacy from a single administration of LAS100977, in stable asthmatic patients.

The release as fetched from its publisher. almirall.com ↗